ATE89566T1 - Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum- produzierten proteins in hepatozyten und zusammensetzungen davon. - Google Patents

Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum- produzierten proteins in hepatozyten und zusammensetzungen davon.

Info

Publication number
ATE89566T1
ATE89566T1 AT88901854T AT88901854T ATE89566T1 AT E89566 T1 ATE89566 T1 AT E89566T1 AT 88901854 T AT88901854 T AT 88901854T AT 88901854 T AT88901854 T AT 88901854T AT E89566 T1 ATE89566 T1 AT E89566T1
Authority
AT
Austria
Prior art keywords
pct
gln
glu
falciparum
hepatocytes
Prior art date
Application number
AT88901854T
Other languages
English (en)
Inventor
Claudine Marchand
Pierre Druilhe
Odile Puijalon-Mercereau
Gordon Langsley
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE89566T1 publication Critical patent/ATE89566T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT88901854T 1987-02-09 1988-02-09 Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum- produzierten proteins in hepatozyten und zusammensetzungen davon. ATE89566T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8701543A FR2610631B1 (fr) 1987-02-09 1987-02-09 Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
EP88901854A EP0343186B1 (de) 1987-02-09 1988-02-09 Moleküle mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum-produzierten proteins in hepatozyten und zusammensetzungen davon
PCT/FR1988/000074 WO1988005785A1 (fr) 1987-02-09 1988-02-09 Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitopes caracteristiques d'une proteine produite par p. falciparum dans les hepatocytes et compositions les contenant

Publications (1)

Publication Number Publication Date
ATE89566T1 true ATE89566T1 (de) 1993-06-15

Family

ID=9347704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88901854T ATE89566T1 (de) 1987-02-09 1988-02-09 Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum- produzierten proteins in hepatozyten und zusammensetzungen davon.

Country Status (8)

Country Link
US (4) US5599542A (de)
EP (1) EP0343186B1 (de)
JP (1) JP2729070B2 (de)
AT (1) ATE89566T1 (de)
AU (1) AU610571B2 (de)
DE (1) DE3881204T2 (de)
FR (1) FR2610631B1 (de)
WO (1) WO1988005785A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2610631B1 (fr) * 1987-02-09 1989-11-24 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
US6270771B1 (en) 1988-10-06 2001-08-07 Institut Pasteur Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
FR2656626B1 (fr) * 1989-12-29 1994-08-12 Pasteur Institut Fragment peptidique comprenant une sequence issue de la proteine 28 kda de schistosoma mansoni et compositions vaccinantes et/ou therapeutiques comprenant ledit fragment.
FR2665365B1 (fr) * 1990-08-06 1995-04-28 Pasteur Institut Antigene de plasmodium falciparum susceptible d'induire des anticorps protecteurs - application a la vaccination.
GB9020438D0 (en) * 1990-09-19 1990-10-31 Imperial College Plasmodium liver stage antigens
FR2697022B1 (fr) 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
GB0022017D0 (en) * 2000-09-08 2000-10-25 Univ Dundee Cell assays
EP1201250A1 (de) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenische Zusammensetzung die hepatische Phaseantigene aus Plasmodium enthält
EP2933334B1 (de) * 2003-02-18 2019-09-18 Baylor College of Medicine Induzierte Aktivierung in dendritischen Zellen
CA3058450A1 (en) * 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
US20100203067A1 (en) 2008-09-22 2010-08-12 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CN105209065B (zh) 2013-03-14 2020-07-31 贝里坤制药股份有限公司 控制t细胞增殖的方法
EP3569253A1 (de) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Verfahren zur induktion von partieller apoptose mithilfe von caspasepolypeptiden
EP3104866A4 (de) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Verfahren zur aktivierung von t-zellen mit einem induzierbaren chimären polypeptid
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
US10189880B2 (en) 2014-11-03 2019-01-29 Leiden University Medical Center T cell receptors directed against Bob1 and uses thereof
WO2016142783A2 (en) 2015-03-10 2016-09-15 Leiden University Medical Center T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
US20210147507A1 (en) 2017-05-09 2021-05-20 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
WO2019113509A2 (en) 2017-12-08 2019-06-13 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569722B2 (en) * 1983-01-28 1988-02-18 Saramane Pty Ltd Expression of plasmodium falciparum polypeptides from cloned cdna
AU584881B2 (en) * 1984-02-21 1989-06-08 British Technology Group Limited Improvements in or relating to the production of malaria vaccines
US4707357A (en) * 1984-06-26 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Immunologically active peptides capable of inducing immunization against malaria and genes encoding therefor
FR2610631B1 (fr) * 1987-02-09 1989-11-24 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
AU4661889A (en) * 1988-11-30 1990-06-26 Biomedical Research Institute A novel malarial sporozoite and exoerythrocytic peptide antigen
US5139792A (en) * 1990-07-19 1992-08-18 Bio-Techniques Laboratories, Inc. Method and system for dispensing live bacteria into animal feed and drinking water

Also Published As

Publication number Publication date
US5928901A (en) 1999-07-27
DE3881204T2 (de) 1993-11-11
EP0343186A1 (de) 1989-11-29
US5599542A (en) 1997-02-04
WO1988005785A1 (fr) 1988-08-11
AU610571B2 (en) 1991-05-23
JP2729070B2 (ja) 1998-03-18
JPH01502194A (ja) 1989-08-03
FR2610631B1 (fr) 1989-11-24
FR2610631A1 (fr) 1988-08-12
US5589343A (en) 1996-12-31
DE3881204D1 (de) 1993-06-24
EP0343186B1 (de) 1993-05-19
US5602031A (en) 1997-02-11
AU1342888A (en) 1988-08-24

Similar Documents

Publication Publication Date Title
ATE89566T1 (de) Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum- produzierten proteins in hepatozyten und zusammensetzungen davon.
NO875476D0 (no) Elektrokjemiluminiscente proever.
ATE211171T1 (de) Weitgehend reine rezeptorartige, tgf-beta-1- bindende moleküle und deren verwendungen
FI946066A (fi) Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
LU91015I2 (fr) Recombinate (Rurioctocog alfa) dans toutes ses formes couvertes par le brevet de base
GB9710809D0 (en) Nucleic acid binding proteins
DE69030124D1 (de) Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C-Virus
NO178665C (no) Fosfopeptider og sammensetning for kosmetiske formål
DE3682893D1 (de) Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen.
ATE94757T1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen.
PT785950E (pt) Analogos do factor de crescimento de queratinocitos
DK0486572T3 (da) Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
Milstein et al. Disulphide bridges of the heavy chain of human immunoglobulin G2
HK1021229A1 (en) A in vitro method of determining the presence of aprotein in an isolated biological sample.
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DE69226775D1 (de) Dns-sequenzen von hpv42 papillomavirus :verwendungsmöglichkeit für diagnose
ATE48142T1 (de) Blutprotein, verfahren zu seiner herstellung, antikoerper gegen dieses protein und dieses protein oder diese antikoerper enthaltende pharmazeutische zubereitungen.
ATE166395T1 (de) Für c.difficile spezifische oligonukleotide
KR960034413A (ko) 아폽토시스 조절 유전자
AU5315790A (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes
KR930701605A (ko) 엠. 튜버쿨로시스(M. tuberculosis)의 단백질 MTP 40의 뉴클레오타이드 및 아미노산 서열 및 이로부터 유도된 합성 펩타이드
PT86944A (pt) Verfahren zur isolierung von basalmembranproteinen aus menschlichen und tierischen geweben
DK292584A (da) Biologisk aktive konjugater, deres fremstilling og anvendelse
BRPI0409948A (pt) composições de spex e processos de uso
MX9206732A (es) Nuevas proteinas inhibidoras de trombina a partir de sanguijuelas de tierra.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time